Avidity Biosciences, Inc.
RNA
$49.77
-$1.00-1.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.73M | 8.93M | 10.90M | 10.12M | 10.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.73M | 8.93M | 10.90M | 10.12M | 10.60M |
| Cost of Revenue | 410.44M | 336.25M | 303.59M | 260.79M | 231.30M |
| Gross Profit | -399.71M | -327.33M | -292.70M | -250.67M | -220.70M |
| SG&A Expenses | 122.08M | 105.94M | 86.24M | 74.02M | 64.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 532.51M | 442.19M | 389.83M | 334.81M | 295.78M |
| Operating Income | -521.78M | -433.27M | -378.94M | -324.69M | -285.18M |
| Income Before Tax | -455.74M | -369.22M | -322.30M | -280.49M | -252.45M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -455.74 | -369.22 | -322.30 | -280.49 | -252.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -455.74M | -369.22M | -322.30M | -280.49M | -252.45M |
| EBIT | -521.78M | -433.27M | -378.94M | -324.69M | -285.18M |
| EBITDA | -518.74M | -430.35M | -376.16M | -322.04M | -282.67M |
| EPS Basic | -3.56 | -3.01 | -2.90 | -2.90 | -2.95 |
| Normalized Basic EPS | -2.22 | -1.88 | -1.81 | -1.81 | -1.85 |
| EPS Diluted | -3.56 | -3.01 | -2.90 | -2.90 | -2.95 |
| Normalized Diluted EPS | -2.22 | -1.88 | -1.81 | -1.81 | -1.85 |
| Average Basic Shares Outstanding | 510.73M | 488.03M | 446.01M | 393.57M | 344.29M |
| Average Diluted Shares Outstanding | 510.73M | 488.03M | 446.01M | 393.57M | 344.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |